United States-based Signant Health has acquired VirTrial, a company that provides software solutions for remote site start-up and decentralised clinical trial conduct, it was reported on Monday.
The acquisition will provide Signant Health with VirTrial's tele-research platform, which includes secure video, audio, chat, and connected medical device capabilities for decentralised patient-site interaction and evaluations and Virtual Site Monitoring to address remote site start-up and monitoring.
Roger Smith, chief executive officer, Signant Health, said, 'COVID-19 has created a widespread and urgent need for contingency planning in clinical trial operations and has forever changed how our industry plans and executes trials. Signant and VirTrial are passionate about supporting the trial ecosystem with software, analytics, and logistics solutions to conduct studies and generate data across all modalities while improving, respecting, and honouring the role investigators and coordinators play in collaborating with patients to advance clinical research. VirTrial's platform is a critical component in our strategy to truly digitise the operations of clinical study sites and bring uniform conduct and evidence generation through a comprehensive set of integrated study management software and services.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients